Cellular diamine levels in cancer chemoprevention: Modulation by ibuprofen and membrane plasmalogens

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Wood, Paul L ^a   Khan, M ^b   Smith, Tara ^b   Goodenowe, Dayan B ^b  

^a Lincoln Memorial University   (United States)

^b Phenomenome Discoveries Inc   (Canada)

Author keywords

cadaverine; cancer chemoprevention; CHO; diamine exporter; ibuprofen; NRel 4; omega 3 fatty acids; ornithine decarboxylase; plasmalogens; PPI 1011; putrescine

Indexed keywords

DIAMINE; IBUPROFEN; PLASMALOGEN; PROSTAGLANDIN SYNTHASE; AMINO ACID; CADAVERINE; CD98 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PUTRESCINE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CHO CELL; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; NONHUMAN; STEREOSPECIFICITY; ANIMAL; CELL MEMBRANE; HAMSTER; METABOLISM; NEOPLASM; PHYSIOLOGY;

CRICETULUS GRISEUS;

AMINO ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD98 HEAVY CHAIN; CADAVERINE; CELL MEMBRANE; CHO CELLS; CRICETINAE; IBUPROFEN; NEOPLASMS; PLASMALOGENS; PUTRESCINE;

EID: 81055150439     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-214     Document Type: Article

References (41)

1. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB, BMC Med 2010 8 13 10.1186/1741-7015-8-13 20156336
2. Identification of metabolites with anticancer properties by computational metabolomics. Arakaki AK, Mezencev R, Bowen NJ, Huang Y, McDonald JF, Skolnick J, Mol Cancer 2008 7 57 10.1186/1476-4598-7-57 18559081 (Pubitemid 352025064)
3. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Casero RA Jr, Marton LJ, Nat Rev Drug Discov 2007 6 373 90 10.1038/nrd2243 17464296 (Pubitemid 46705201)
4. Polyamine catabolism and disease. Casero RA, Pegg AE, Biochem J 2009 421 323 38 10.1042/BJ20090598 19589128
5. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Martinez ME, O'Brien TG, Fultz KE, Babbar N, Yerushalmi H, Qu N, Guo Y, Boorman D, Einspahr J, Alberts DS, Gerner EW, Proc Natl Acad Sci USA 2003 100 7859 64 10.1073/pnas.1332465100 12810952 (Pubitemid 36760060)
6. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW, Gastroenterology 2010 139 797 805 10.1053/j.gastro.2010.06.005 20538001
7. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Harris RE, Beebe-Donk J, Doss H, Burr Doss D, Oncol Rep 2005 13 559 83 15756426
8. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. Meyskens FL Jr, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, Lagerberg W, J Natl Cancer Inst 1998 90 1212 8 10.1093/jnci/90.16.1212 9719082 (Pubitemid 28407087)
9. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenoma. Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW, Meyskens FL, Cancer Prev Res (Phila) 2009 2 209 12 10.1158/1940-6207.CAPR- 08-0203
10. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. Mahmud SM, Franco EL, Turner D, Platt RW, Beck P, Skarsgard D, Tonita J, Sharpe C, Aprikian AG, PLoS One 2011 6 16412 10.1371/journal.pone.0016412 21297996
11. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL Jr, Cancer Epidemiol Biomarkers Prev 2008 17 292 9 10.1158/1055-9965.EPI-07-0658 18268112 (Pubitemid 351272778)
12. Prostaglandin-independent effects of aspirin on cell cycle and putrescine synthesis in human colon carcinoma cells. Eklou-Kalonji E, Andriamihaja M, Reinaud P, Mayeur C, Camous S, Robert V, Charpigny G, Blachier F, Can J Physiol Pharmacol 2003 81 443 50 10.1139/y03-058 12774850 (Pubitemid 36605555)
13. Targeting polyamines and inflammation for cancer prevention. Babbar N, Gerner EW, Recent Results Cancer Res 2011 188 49 64 21253788
14. Regulation of ornithine decarboxylase. Pegg AE, J Biol Chem 2006 281 14529 32 10.1074/jbc.R500031200 16459331 (Pubitemid 43855154)
15. Polyamines and the intestinal tract. Seiler N, Raul F, Crit Rev Clin Lab Sci 2007 44 365 411 10.1080/10408360701250016 17558654 (Pubitemid 46897708)
16. Catabolism of polyamines. Seiler N, Amino Acids 2004 26 217 33 15221502 (Pubitemid 38829785)
17. Polyamine transport systems in mammalian cells and tissues. Uemura T, Gerner EW, Methods Mol Biol 2011 720 339 48 10.1007/978-1-61779-034-8-21 21318884
18. Identification and characterization of a diamine exporter in colon epithelial cells. Uemura T, Yerushalmi HF, Tsaprailis G, Stringer DE, Pastorian KE, Hawel L, Byus CV, Gerner EW, J Biol Chem 2008 283 26428 35 10.1074/jbc.M804714200 18660501
19. Plasmalogens the neglected regulatory and scavenging lipid species. Wallner S, Schmitz G, Chem Phys Lipids 2011 164 573 89 10.1016/j.chemphyslip. 2011.06.008 21723266
20. Fatty acid facts, part II: role in the prevention of carcinogenesis, or, more fish on the dish? Pauwels EK, Kairemo K, Drug News Perspect 2008 21 504 10 10.1358/dnp.2008.21.9.1290819 19180268
21. Regulation of colorectal cancer cell apoptosis by the n-3 polyunsaturated fatty acids Docosahexaenoic and Eicosapentaenoic. Giros A, Grzybowski M, Sohn VR, Pons E, Fernandez-Morales J, Xicola RM, Sethi P, Grzybowski J, Goel A, Boland CR, Gassull MA, Llor X, Cancer Prev Res (Phila) 2009 2 732 42 10.1158/1940-6207.CAPR-08-0197
22. A reliable biomarker derived from plasmalogens to evaluate malignancy and metastatic capacity of human cancers. Smith RE, Lespi P, Di Luca M, Bustos C, Marra FA, de Alaniz MJ, Marra CA, Lipids 2008 43 79 89 10.1007/s11745-007-3133-6 18046593
23. Identification of phospholipid scramblase 1 as a biomarker and determination of its prognostic value for colorectal cancer. Kuo YB, Chan CC, Chang CA, Fan CW, Hung RP, Hung YS, Chen KT, Yu JS, Chang YS, Chan EC, Mol Med 2011 17 41 7 20927484
24. Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. Munn NJ, Arnio E, Liu D, Zoeller RA, Liscum L, J Lipid Res 2003 44 182 92 10.1194/jlr.M200363-JLR200 12518037 (Pubitemid 36114784)
25. Plasmalogen Deficit: A New and Testable Hypothesis for the Etiology of Alzheimer's Disease. Wood PL, Khan A, Mankidy R, Smith T, Goodenowe DB, Open Access in Alzheimers Disease-Book 2 2011 ISBN 979-953-307-022-2
26. Targeted metabolomic analyses of cellular models of pelizaeus-merzbacher disease reveal plasmalogen and myo-inositol solute carrier dysfunction. Wood PL, Smith T, Pelzer L, Goodenowe DB, Lipids Health Dis 2011 10 102 10.1186/1476-511X-10-102 21682894
27. In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor. Wood PL, Khan MA, Smith T, Ehrmantraut G, Jin W, Cui W, Braverman NE, Goodenowe DB, Lipids Health Dis 2011 10 182 22008564
28. Characterization of a diamine exporter in Chinese hamster ovary cells and identification of specific polyamine substrates. Xie X, Gillies RJ, Gerner EW, J Biol Chem 1997 272 20484 9 10.1074/jbc.272.33.20484 9252359 (Pubitemid 27355603)
29. Of timing and surrogates-A way forward for cancer chemoprevention. Thompson P, Gerner EW, Clin Cancer Res 2011 17 3509 11 10.1158/1078-0432.CCR-11- 0643 21498391
30. Free and acetylated polyamines as markers of oral cavity tumors. Gallesio C, Colombatto S, Modica R, Oral Surg Oral Med Oral Pathol 1994 77 167 71 10.1016/0030-4220(94)90280-1 8139835
31. Polyamine concentrations in pancreatic tissue, serum, and urine of patients with pancreatic cancer. Löser C, Fölsch UR, Paprotny C, Creutzfeldt W, Pancreas 1990 5 119 27 10.1097/00006676-199003000-00001 2315288 (Pubitemid 20074052)
32. Polyamines in colorectal cancer. Evaluation of polyamine concentrations in the colon tissue, serum, and urine of 50 patients with colorectal cancer. Löser C, Fölsch UR, Paprotny C, Creutzfeldt W, Cancer 1990 65 958 66 10.1002/1097-0142(19900215)65:4<958::AID-CNCR2820650423>3.0.CO;2-Z 2297664 (Pubitemid 20063503)
33. Diamine-oxidase activity and tissue di- and poly-amine contents of human ovarian, cervical and endometrial carcinoma. Chanda R, Ganguly AK, Cancer Lett 1995 89 23 8 7882298
34. Regulation of putrescine export in lipopolysaccharide or IFN-gamma-activated murine monocytic-leukemic RAW 264 cells. Tjandrawinata RR, Hawel L, Byus CV, J Immunol 1994 152 3039 52 8144903 (Pubitemid 24098003)
35. Biosynthesis and selective export of 1,5-diaminopentane (cadaverine) in mycoplasma-free cultured mammalian cells. Hawel L, Tjandrawinata RR, Fukumoto GH, Byus CV, J Biol Chem 1994 269 7412 8 8125959 (Pubitemid 24217940)
36. Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. Babbar N, Gerner EW, Casero RA Jr, Biochem J 2006 394 317 24 10.1042/BJ20051298 16262603 (Pubitemid 43259681)
37. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. Grösch S, Tegeder I, Niederberger E, Bräutigam L, Geisslinger G, FASEB J 2001 15 2742 4 11606477
38. Membrane plasmalogen composition and cellular cholesterol regulation: a structure activity study. Mankidy R, Ahiahonu PW, Ma H, Jayasinghe D, Ritchie SA, Khan MA, Su-Myat KK, Wood PL, Goodenowe DB, Lipids Health Dis 2010 9 62 10.1186/1476-511X-9-62 20546600
39. Peroxisomal disease cell lines with cellular plasmalogen deficiency have impaired muscarinic cholinergic signal transduction activity and amyloid precursor protein secretion. Périchon R, Moser AB, Wallace WC, Cunningham SC, Roth GS, Moser HW, Biochem Biophys Res Commun 1998 248 57 61 10.1006/bbrc.1998.8909 9675085 (Pubitemid 28418186)
40. Plasmalogen content and beta-adrenoceptor signalling in fibroblasts from patients with Zellweger syndrome. Effects of hexadecylglycerol. Styger R, Wiesmann UN, Honegger UE, Biochim Biophys Acta 2002 1585 39 43 10.1016/S1388-1981(02)00320-7 12457713 (Pubitemid 35375854)
41. Oligodendrocyte substratum adhesion modulates expression of adenylate cyclase-linked receptors. Vartanian T, Sprinkle TJ, Dawson G, Szuchet S, Proc Natl Acad Sci USA 1988 85 939 43 10.1073/pnas.85.3.939 2448785 (Pubitemid 18073942)